March 4, 2015

Arrowhead to Present at 2015 Barclays Global Healthcare Conference

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Research Corporation (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that Arrowhead's president and chief executive officer Christopher Anzalone, Ph.D., will present at the 2015 Barclays Global Healthcare Conference on March 11, 2015 at 1:35 p.m. EST. Investors may access live and archived versions of the audio webcast of this presentation on the Company's website at http://ir.arrowheadresearch.com/events.cfm.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary Dynamic Polyconjugate delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead's pipeline includes ARC-520 for chronic hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1 antitrypsin deficiency, and partner-based programs in obesity and oncology.

For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadresearch.com/alerts.cfm.

Source: Arrowhead Research Corporation

Arrowhead Research Corporation
Vince Anzalone, CFA, 626-304-3400
ir@arrowres.com
or
Investor Relations:
The Trout Group
Todd James, 646-378-2926
ir@arrowres.com
or
Media:
Russo Partners
Matt Middleman, M.D., 212-845-4272
matt.middleman@russopartnersllc.com

Source: Arrowhead Research Corporation

News Provided by Acquire Media